The Mid-Term Efficacy and Safety of a Permanent Nitinol IVC Filter (TrapEase) by Liu, Wei Chiang et al.
110 Korean J Radiol 6(2), June 2005
The Mid-Term Efficacy and Safety of a
Permanent Nitinol IVC Filter (TrapEase)
Objective: 1) To evaluate the mid-term efficacy and safety of a permanent niti-
nol inferior vena cava (IVC) filter; 2) to evaluate filter effectiveness, filter stability
and caval occlusion.
Materials and Methods: A prospective evaluation of the TrapEase IVC filter
was performed on 42 patients (eight men, 34 women) ranging in age from 22 to
78 years (mean age 66 years). All patients were ill with a high risk of pulmonary
embolism (PE). Indications for filter placement were: 1) deep vein thrombosis
with recurrent thromboembolism; 2) and/or free-floating thrombus with contraindi-
cation to anticoagulation; and 3) complications in achieving adequate anticoagu-
lation. Follow-up evaluations (mean: 15.4 months, range: 2 to 28 months) were
performed at 6- and 12-month intervals after the procedure and included clinical
histories, chart reviews, plain film, Doppler ultrasounds, and contrasted abdomi-
nal CT scans.
Results: In follow-up evaluations, the data analysis revealed no cases of
symptomatic PE. There were no cases of filter migration, insertion site thrombo-
sis, filter fracture, or vessel wall perforation. During the study, there was one case
of filter thrombosis; early symptomatic thrombosis that was successfully treated in
the hospital. Of the 42 subjects, eight died. These deaths were not related to the
filter device or the implantation procedure, but to the underlying disease.
Conclusion: This study demonstrates that the TrapEase permanent IVC filter
is a safe and an effective device with low complication rates and is best used in
patients with thromboembolic disease with a high risk of PE.
ercutaneous filter placement to achieve a partial mechanical interruption
of the inferior vena cava (IVC) is well established as a method of prevent-
ing life threatening pulmonary embolism (PE) caused by lower extremity
deep vein thrombosis (DVT). The implantation of a permanent vena cava filter in the
IVC is viewed largely as an alternative therapy when anticoagulation therapy in
patients with thromboembolic disease fails or is contraindicated. Since its inception in
1967, the first IVC filter (1) has spawned various configurations that have been
developed and subsequently improved in line with increased clinical applications and
knowledge. However, an ideal filter device has yet to be developed. The long-term
performance and small incidence of filter complications are particularly important in
patients being considered for prophylactic IVC filter insertion. The nitinol permanent
IVC filter (TrapEase; Cordis Europa, Roden, Netherlands) was designed with low
profile (6-F) characteristics intended to ensure the protection of PE with a theoretically
low risk of filter-associated complications. A multi-institutional study of the TrapEase
filter reported a six month follow-up (2). Our experiences with the TrapEase filter
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Pplacement with a one year follow-up at a single institution
are reported herein.
MATERIALS AND METHODS
Study Group
From April 2001 to August 2002, a TrapEase filter was
placed into the inferior vena cava (IVC) of 48 consecutive
patients. Of the 48 patients, four were lost to follow-up
and two refused to complete study 42 patients (8 men, 34
women; mean age: 66, age range: 22 78 years) were
prospectively enrolled into the study protocol. Clinical
histories were evaluated for indication of filter placement.
Pertinent coexisting medical and surgical conditions were
recorded. This prospective study was approved by our
Institutional Review Board. Written informed consent was
obtained from all patients after the nature of the
procedures was fully explained.
Study Endpoints
The primary study objective was to evaluate the
effectiveness of the filter in preventing major complications
in patients who have venous thromboembolic disease and
were clinically judged to be at high risk of pulmonary
embolism. The secondary objectives were to assess: 1) the
stability of the filter in the IVC during the 12-month
follow-up period; and 2) the rate of caval (and/or filter)
occlusion. 
Indications
The indications for filter placement were: 1) pulmonary
embolism (PE) with a contraindication to anticoagulation
in 14 patients; 2) recurrent PE in spite of anticoagulation in
14 patients; 3) iliofemoral deep venous thrombosis (DVT)
with a contraindication to anticoagulation in nine patients;
and 4) patients with free-floating thrombus in five patients.
Either PE or DVT was diagnosed in all patients by means
of an objective test prior to filter placement: PE with either
ventilation/perfusion scanning (n=13, 31%) or pulmonary
CT angiography (n=29, 69%) and DVT with either
contrasted CT (n=25, 60%) or duplex sonography (n=17,
40%).
Exclusion criteria were pregnancy, uncontrolled
infectious diseases, caval diameters larger than 30 mm, life
expectancies of less than three months, and current
enrollment in other medical investigations.
Filter Design and Deployment
The filter used was a double-basket, symmetric nitinol
vena cava filter (TrapEase) laser cut from nickel-titanium
(nitinol) tubing. The filter has a non-expanded maximum
length of 65 mm. When expanded to its maximum
diameter (35 mm in vitro), the length reduced to 50 mm.
The cephalic and caudal baskets of the filter consist of
struts in a six diamond or trapezoidal configuration. The
baskets are then connected by six straight struts, which
contain proximal and distal hooks for fixation within the
IVC. The filter is implanted through a 6-F straight
introducer sheath (55 cm long) with a radiopaque marker
at the distal tip. A pusher advances the filter through the
sheath to the implantation site (Figs. 1A, B). This
introducer system increases the speed and efficiency of the
procedure.
Before implantation, the diameter of the IVC was
assessed by cavography by means of contour marking of
the angiographic catheter to determine eligibility for study
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Fig. 1. A, B. Frontal (A) and lateral (B) views of the TrapEase inferior vena cava filter.
ABinclusion (16 30 mm). By using a standard percutaneous
procedure, the long 6-F (filter delivery) sheath was
introduced under fluoroscopy via either the jugular vein or
the femoral vein over a standard 0.035-inch guide wire to
the intended implantation site in the IVC. After removing
the guide wire, the filter was introduced into the sheath
and advanced to the tip of the sheath by means of the
pusher. Once it was determined that the filter was in the
correct position in the IVC, the sheath was retracted. By
this means, the filter was deployed immediately below the
renal veins. An anteroposterior and lateral projection plain
radiography was performed to determine the final position
of the filter in the IVC. Nineteen patients were maintained
on anticoagulation following filter placement.
Follow-up
Patients underwent duplex Doppler US of their lower
limbs and an abdominal CT scan to identify any underlying
diseases. Baseline ventilation-perfusion scanning and chest
radiographies were performed before filter implantation.
Subsequent lung scintigraphy and chest radiography were
indicated only when symptoms indicating clinically
symptomatic PE arose (dyspnea, with thoracic pain and
positive blood gas measurements, hypotension, cardiac
anomalies, failing consciousness, or lack of consciousness).
A 24-hour follow-up examination before hospital
discharge included abdominal radiography, Duplex
Doppler US (ATL HDI-3000, Advanced Technology
Laboratories, Bothell, WA) and a clinical examination.
Follow-up at six (n=37) and 12 months (n=34) included
chest radiography, abdominal radiography, and contrast
enhanced abdominal CT (Lightspeed Ultra 16, GE Medical
System, Milwaukee, WI) of the filter to evaluate filter
effectiveness, stability and caval obstruction. Filter
migration (either caudal or cranial of more than one
vertebra) as seen in abdominal radiography, or filter tilt of
more than 150 from the axis of the IVC, was considered
positive.
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Fig. 2. A. A 42-old women with Behcet disease had symptomatic
inferior vena cava obstruction after inferior vena cava filter
placement (black arrow).
B. Thrombus was still detected at 1-month follow-up CT (black
arrow).
C. Patient underwent anticoagulation therapy during the entire
follow-up period. The thrombus was completely resolved at 6-
month follow-up CT (white arrow).
CRESULTS
Before commencing filter implantation, the mean
diameter of the IVC was assessed to be 20.8 mm (range:
16 30 mm). The filter was placed in 34 patients via the
right jugular vein and in eight patients via the right femoral
vein. The level of implantation in the IVC, using the
thoracic and lumbar vertebrae as a reference, was T11-12
in five patients, L1-2 in one patient, L2-3 in 20 patients,
L3-4 in 15 patients and L4-5 in one patient. Thirty-seven
filters (88%) were placed in the infrarenal location. Five
filters (12%) were placed in a suprarenal location because
of an extension of the thrombus into the infrarenal IVC
(n=4) and double IVC (n=1).
After the 24-hour follow-up exam, there were no reports
of filter-related symptomatic PE (0%). There were no
reports of hematoma or insertion site complications when
the insertion site was controlled by means of duplex and
clinical examinations. Abdominal radiography performed
during this period to ascertain filter stability (migration) in
the vena cava showed no cases of filter migration or other
filter-related complications.
There was one case of symptomatic IVC obstruction by
filter thrombosis during hospitalization. This patient had
underlying Behcet disease and DVT with free-floating IVC
thrombosis. Lower leg swelling was aggravated after filter
placement. A one-week follow-up by contrast enhanced
abdominal CT scan showed total an IVC obstruction under
the filter level (Fig. 2A). This IVC obstruction was success-
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Fig. 3A. A 64-old women had symptomatic pulmonary thromboembolism (white arrow).
B. Patient underwent anticoagulation therapy during the entire follow-up period, the pulmonary embolism completely resolved at 1-year
follow-up (white arrow).
AB
Fig. 4A, B. Abdominal CT demonstrates normal central placement of inferior vena cava filter without wall penetration or tilt (black and
white arrow).
ABfully treated with intravenous urokinase and heparin.
Thrombus was still detected in the one-month follow-up
CT (Fig. 2B). This patient underwent anticoagulation
therapy during the entire follow-up period. The thrombus
was found to be completely resolved in the 6- and 12-
month follow-up intervals using contrast abdominal CTs
(Fig. 2C).
During the follow-up period (mean:15.4 months, range:
2 to 28 months), no cases of recurrent symptomatic PE
(Figs. 3A, B), IVC thrombosis, filter migration, filter
breakage or vessel wall perforation were observed (Figs.
4A, B) at simple radiography and contrast abdominal CT.
Eight patients (19%) in this study group died after filter
placement: three at two months, two at four months, one
at eight, nine, 11 months, respectively. All deaths were
judged by the clinician not to be caused by recurrent
pulmonary embolism but rather by the underlying disease
process: cervical carcinoma (n=2), pancreatic adenocarci-
noma (n=2), urogenic sepsis (n=1), intracranial
hemorrhage (n=1), liver crirrhosis with spontaneous
bacterial peritonitis (n=1) and ovarian cancer (n=1).
DISCUSSION
Presently, there are seven devices for percutaneous IVC
interruption approved by the US Food and Drug
Administration (FDA); the stainless steel Greenfield filter,
the titanium Greenfield filter (Boston Scientific/Medi-tech,
Watertown, MA), the Bird s Nest filter, Gunter Tulip filter
(Cook, Bloomington, IN), the Simon nitinol filter (Nitinol
Medical Technologies, Woburn, MA), VenaTech low-
profile filter (Braum Venatech, Evanston, IL), and
TrapEase filter (Cordis, Europa N.V., L.J. Roden, The
Netherlands). Despite the popularity of these IVC filters,
there has been no prospective clinical study comparing the
effectiveness and complications associated with the differ-
ent filter designs. None of these devices is ideal. Thus, the
search for an ideal device continues (3).
Insertion of IVC filters offers protection from life-threat-
ening PE while subjecting the patient to a small incidence
of associated filter complications. The major complications
related to the insertion of permanent IVC filters are
insertion site thrombosis, filter migration, strut erosion
through the IVC wall, recurrent pulmonary embolism, IVC
obstruction and lower extremity venous insufficiency (4).
Thrombotic complications after filter placement, another
key IVC filter attribute, may in fact be a major discriminat-
ing variable among the design. Thrombosis associated with
IVC filters occurs in two instances - outright IVC thrombo-
sis and access-site thrombosis. Caval obstruction and/or
filter thrombosis reported varies widely (0 28%) (5).
Filter occlusion may result from successful clot trapping.
An initial partial occlusion may develop into a total
occlusion. Or, occlusion may be due to the presence of the
device in the vena cava. In filter occlusion, it is difficult to
determine which of the two possibilities could have been
responsible for the event. Although thrombosis due to
successful clot trapping by the filter is an undesired event,
it represents a trade-off situation between possible
thrombosis and potentially fatal PE due to inadequate clot
trapping. In this study, one case of caval obstruction by
filter thrombosis occurred during hospitalization, which
was successfully treated with intravenous urokinase and
heparin.
Access site thrombosis is a serious complication because
it poses an additional risk for patients with PE. The size of
the introducer system is important in minimizing the risk
for incidence of insertion site thrombosis. In the days after
filter implantation, femoral insertion of the titanium
Greenfield filter (14 F outer diameter introducer system)
was reported to give a high incidence of insertion site
thrombosis (ranging between 19 41% (6, 7) and 28% for
the Simon nitinol filter with a smaller introducer sheath
(7 F) (8)). The introducer sheath for the TrapEase IVC
filter uses only a 6-F diameter, which is the smallest system
of all vena cava filters currently available. In this study,
Duplex US of the insertion site revealed there was no case
(0%) of hematoma. There were no cases of
thrombophlebitis at the site of implantation between 24
hours and discharge. In addition, there were no other
complications that are known to be associated with filter
insertion, such as air embolism, PE due to freed or
dislodged thrombus as a result of catheter manipulation
and wound infection. We believe that none of insertion site
complications were due to filter placement through the
right jugular vein and smaller introduce sheath (9, 10).
Filter migration has had a variation of definitions in all
the manuscripts the authors mention making head-to-head
comparisons difficult. Filter migration is a complication
because of the potentially fatal consequences. The risks
include migration to a location or position where the
device no longer protects against PE or embolization of the
filter into the heart or pulmonary artery. Distal filter
migration occurred most often, and the incidence was 0-
53% in the most frequently deployed filters (8, 11 15).
Rose et al. (11) found movement in 28 of 53 patients
(53%) with routine follow roentgenograms. The newer
filter designs have not prevent migration. To detect distal
or proximal filter migration, abdominal radiography must
be performed. Some of the reported filter movement may
have been secondary to measurement errors, since changes
less than 0.5 cm could come from patient positioning,
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study, controlled abdominal radiography was performed at
day one or earlier and at one, six, and 12 months after
implantation. There were no cases of migration.
Malpositioning can include tilting of the filter, asymme-
try or entwining of struts of the device, and improper
anatomic placement. Tilting and the asymmetric position-
ing of the device can lead to decreased filter filtration or
effectiveness because of the larger-than-intended spaces
between the filter struts. This can increase the risk for
larger-than-intended size thrombi to pass through the filter
and, inadvertently, into the lungs. Tilting has been
observed in the Venatech filter in as many as 16% of the
placements (12). Asymmetry or the entwining of struts has
been reported with the titanium Greenfield filter at an
incidence of up to 71% (16). In this study, there was no
case of tilting or asymmetry. The design of the TrapEase
filter would appear to be such that the chance of tilting and
asymmetric placement are minimized because of the long
side struts being directly connected to the proximal and
distal baskets. This may reduce the possibility of individual
side struts attaching asymmetrically to the vessel walls
during filter release.. Improper placement of the filter has
been reported to occur in the heart (17), renal vein (3),
spermatic vein, iliac vein (18), lumbar vein (19), and
suprarenal caval vein (20). All filters were implanted in the
IVC in this study.
Experiments using both the titanium Greenfield and the
stainless steel Greenfield filters deployed in sheep showed
that all filters demonstrated IVC penetration at one or
more sites over a 12-month period. Histological analysis
revealed intimal remodelling, chronic inflammation, and
adventitial thinning around the hook sites (21). In the
review of collected case series, IVC wall penetration was
found to occur in 4% of titanium Greenfield filters, 37% of
Simon Nitinol filters, and 38% of Bird s Nest filter (5). In
the MGH series, nine out of 96 patients who underwent
autopsies had evidence of IVC penetration (15). None of
these patients died as a result of this finding. Although one
of the criticisms of TrapEase is the issue of radial force and
possible caval rupture, there was no case of caval wall
penetration and retroperitoneal hemorrhage on follow-up
contrasted abdominal CT in this study.
Recurrent PE following IVC filtration has been reported
to range from 2 6% (1), with fatal PE occurring in 0.8
3.7% of the cases (22, 23). Embolus can occur through or
from the filter or via collateral pathways, particularly
where there has been well-developed caval thrombosis and
collateral veins. This study had no cases of recurrent
symptomatic PE. Symptoms of PE in early follow-ups were
reported to be related to the preimplantation status of the
patient and did not signify a worsening of the pulmonary
status because of possible recurrent PE. No incidence of
recurrent symptomatic PE in our series suggests the
TrapEase filter is effective at clot trapping.
The TrapEase IVC filter has several advantages over
currently available filters. First, the TrapEase has the
smallest introducer system of all permanent IVC filters
(6F), thereby reducing the risk of insertion site complica-
tions (10). Its double-basket, symmetric design with long
connecting side struts appears to provide a low risk of
tilting, a phenomenon often observed with umbrella filters.
Thus, the risk of compromised clot trapping is reduced. In
addition, the symmetry of the filter not only allows for the
introduction through both jugular and femoral routes with
a single kit but also removes the risk of a filter being
incorrectly implanted, as could occur with asymmetric
devices. Another advantage of the small-sized sheath is the
option of introducing the filter by a brachial approach (24).
A long-term follow-up of patients treated with IVC filters
is difficult because of their age and poor health condition.
Further, most recurrent PE are asymptomatic. As noted by
other authors, 20 45% of patients (mean: 30%) died
within the first year following filter implantation (25, 26).
In this study, eight patients (19%) died in the first 12
months of using an IVC filter placement due to underlying
diseases. The mortality rate was related to the underlying
disease, mainly due to cancer (50%), which appeared to be
the only predicting prognostic factor in this study.
Even though the follow-up period is short, the 6-F
TrapEase permanent IVC filter is a safe, effective device
with a low overall complication rate that can be used for
thromboembolic disease with a high risk of PE.
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